The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there is a randomized placebo-controlled trial that began in China on February 14th investigating the effect of high-dose intravenous vitamin C on severe Koba 19 infected pneumonia the study will treat severe Koba 19 patients with 12 grams of intravenous vitamin C twice a day for a total of 24 grams of intravenous vitamin C for seven days
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
one physician in China used was treating 50 cases of moderate to severe Koba 19 with high intravenous vitamin C the dose ranging from 10 to 20 grams a day for seven to ten days with 10 grams for moderate cases and 20 grams for the more severe cases all patients who receive the intravenous vitamin C according to the anecdote improved and there was no mortality compared to the average of a 30 day hospital stay for Koba 19 patients those patients who received high-dose intravenous vitamin C had a hospital stay about 3 to 5 days shorter than the overall patients
there is some anecdotal evidence from correspondence from physicians in China that have been using intravenous vitamin C to treat complications associated with Koba 19 these correspondences are not peer reviewed they're essentially anecdotes from from physicians that have been posted on websites